ClinicalTrials.gg
CompletedNCT00595413AUGUST IIUpdated Feb 17, 2016Results posted

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

A Phase 2 interventional study of Placebo matched to atacicept and Atacicept: with loading dose in Rheumatoid Arthritis, sponsored by EMD Serono. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
200th of 771
311 · median 120
Started
2007
with 50 others
Phase 2
215 of 975
12 open now
Registered
202nd of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 200th largest by enrollment of the 771 interventional ones that give a count, is one of 51 that started in 2007, is one of 215 in phase 2, and was the 202nd registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • Atacicept
  • Adalimumab
  • Humira®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects greater than or equal to (>=) 18 years of age at the time of who have RA satisfying American College of Rheumatology (ACR) criteria with a disease history of at least 6 months
  • Subjects must have active disease, defined by >=8 swollen joints (out of 66), >=8 tender joints (out of 68) and CRP >=10 milligram per liter (mg/L) and/or erythrocyte sedimentation rate (ESR) >=28 millimeter per hour (mm/hr), despite treatment with MTX at a dose of >=15 milligram per week (mg/week) for greater than (>) 3 months
  • Other protocol-defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Inflammatory joint disease other than RA
  • Previous or concurrent treatment with any approved or biological compound for RA, including but not restricted to any anti-TNFalpha agents, rituximab, abatacept, tocilizumab, interleukin-1 receptor antagonist (IL-1Ra) and belimumab
  • Treatment with disease-modifying anti-rheumatic drug (DMARDs) other than MTX
  • Participation in any interventional clinical trial within 1 month before study Day 1
  • MTX dose >25 mg/week, prednisone dose >10 mg/day (or equivalent), or change in or non-steroidal anti-inflammatory drug (NSAID) dosing regimen within 28 days before study Day 1
  • Immunization with or immunoglobulin (Ig) treatment within 28 days before study Day 1 or need for such treatment during the study (including follow-up)
  • Any history or presence of active or latent tuberculosis, major infection requiring hospitalization or intravenous anti-infectives within 28 days before study Day 1
  • Other major concurrent illness or organ dysfunction as specified in the protocol
  • Serum IgG below 6 gram per liter (g/L)
  • Known to atacicept or to any of the components of the formulated atacicept
  • Other protocol-defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Atacicept 150 mg with loading dose

    Drug: Atacicept: with loading dose

  • Experimental
    Atacicept 150 mg without loading dose

    Drug: Atacicept

  • Active comparator
    Adalimumab

    Biological: Adalimumab

  • Placebo comparator
    Placebo

    Drug: Placebo matched to atacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26

    ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26

    ACR50-CRP response is defined as \>=50% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

    Time frame: Week 26

  2. Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26

    ACR70-CRP response is defined as \>=70% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

    Time frame: Week 26

  3. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26

    The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was less than or equal to (\<=) 5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.

    Time frame: Week 26

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

    Time frame: From the first dose of study drug up to 30 days after the last dose of study drug, assessed up to Week 38

07

Results

Posted Feb 17, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
Started76787879
Completed69737075
Not completed7584
Withdrew: Adverse event0211
Withdrew: Lost to follow-up2213
Withdrew: Death0010
Withdrew: Other5150

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26

ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26
percentage of participantsPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 2646.144.957.770.9
SecondaryPercentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26

ACR50-CRP response is defined as \>=50% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26
percentage of participantsPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 2614.529.533.338.0
SecondaryPercentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26

ACR70-CRP response is defined as \>=70% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26
percentage of participantsPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 265.312.812.817.7
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26

The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was less than or equal to (\<=) 5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26
percentage of participantsPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 2659.264.167.981.0
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

Time frame:
From the first dose of study drug up to 30 days after the last dose of study drug, assessed up to Week 38
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
participantsPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
TEAEs38494950
Serious TEAEs2473

Adverse events

Collected over From the first dose of study drug up to 30 days after the last dose of study drug, assessed up to Week 38. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/76 (2.6%)23/76 (30.3%)
Atacicept 150 mg With Loading Dose—4/78 (5.1%)27/78 (34.6%)
Atacicept 150 mg Without Loading Dose—7/78 (9%)24/78 (30.8%)
Adalimumab—3/79 (3.8%)22/79 (27.8%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
PneumoniaInfections and infestations0/760/780/782/79
CellulitisInfections and infestations1/760/780/780/79
PericarditisCardiac disorders1/760/780/780/79
Tendon ruptureInjury, poisoning and procedural complications1/760/780/780/79
DyspnoeaRespiratory, thoracic and mediastinal disorders0/760/781/780/79
Laryngeal oedemaRespiratory, thoracic and mediastinal disorders0/761/780/780/79
Obstructive airways disorderRespiratory, thoracic and mediastinal disorders0/760/781/780/79
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/760/781/780/79
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders0/760/781/780/79
OsteoarthritisMusculoskeletal and connective tissue disorders0/761/780/780/79
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumab
NasopharyngitisInfections and infestations6/762/784/785/79
BronchitisInfections and infestations4/765/786/783/79
Upper respiratory tract infectionInfections and infestations2/764/784/786/79
SinusitisInfections and infestations0/765/781/780/79
HypertensionVascular disorders4/763/782/781/79
LeukopeniaBlood and lymphatic system disorders4/761/781/783/79
PharyngitisInfections and infestations1/763/784/783/79
HeadacheNervous system disorders3/764/784/782/79
CoughRespiratory, thoracic and mediastinal disorders2/763/784/782/79
Urinary tract infectionInfections and infestations3/764/784/782/79

Baseline characteristics

Intention-to-treat (ITT) population included all randomized participants who received at least 1 study treatment dose.

Age, Continuous
Age, Continuous(years)PlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumabTotal
Mean54.0 ± 10.353.0 ± 11.353.3 ± 13.253.3 ± 11.553.4 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtacicept 150 mg With Loading DoseAtacicept 150 mg Without Loading DoseAdalimumabTotal
Female64656664259
Male1213121552
08

Study locations

2 sites
  • Please Contact US Medical Information
    Rockland, Massachusetts, United States
  • Please contact the Merck KGaA Communication Center
    Darmstadt, Germany
09

References and documents

Publications

  • van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011 Jul;63(7):1782-92. doi: 10.1002/art.30372. PubMed 21452294 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 6 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2008
First posted
Jan 16, 2008
Start
Sep 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Feb 17, 2016
Last update
Feb 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00595413
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Jan 16, 2008
Start date
Sep 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Feb 17, 2016
Last update
Feb 17, 2016

Study contacts

Medical Responsible
study director · Merck Serono International SA, an affiliate of Merck KGaA Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein

Start the discussion